Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Otsuka Pharmaceutical Co., Ltd. Subscribes to Celera Discovery System

Rockville, MD - November 19, 2001

Celera Genomics (NYSE: CRA), an Applera Corporation business, announced today that Otsuka Pharmaceutical Co., Ltd., has signed a multi-year subscription agreement with Celera. Otsuka researchers will access the Celera Discovery System™ (CDS) to use Celera's database products, bioinformatics systems, and other discovery tools in their research. Financial terms of the agreement were not disclosed.

“We are pleased that research driven, forward-looking companies like Otsuka realize the important role that genomics is playing in drug discovery efforts and have chosen to subscribe to the Celera Discovery System,” said J. Craig Venter, Ph.D., Celera’s president and chief scientific officer. “We believe the tools, software and data that we provide for our customers through CDS are key to allowing research programs to manage the growing levels of genomic data.”

The Celera Discovery System is an integrated, web-based platform that enables users to leverage Celera’s computational tools, super-computing power, and the genomic and biological databases to advance the discovery process for researchers worldwide.

“Integrating our research data into Celera’s database, we can vigorously accelerate the process of genomic-based research programs,” said Max Yoshitake, Otsuka’s board member in charge of genomic research. “Particularly, our extensive research of disease models and SNP analyses will be strengthened and expanded by Celera’s database. This integration will shed light on Otsuka’s novel drug discovery and development.”

About Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd. (Otsuka) is a diversified health care company dedicated to the research and development of innovative medical, pharmaceutical and nutritional products to improve the quality of human life. Under the corporate theme “Otsuka, people creating new products for better health worldwide,” Otsuka is committing itself to therapeutic areas including cardiovascular, central nervous system, gastrointestinal, and respiratory treatments and actively pursuing genomic research. The company is part of the Otsuka Group, being headquartered in Tokyo, Japan and comprised of more than 23 businesses and 13,500 employees worldwide, earning total revenues of more than $4 billion annually. http://www.otsuka.co.jp

About Applera Corporation and Celera Genomics
Applera Corporation comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, is engaged principally in integrating advanced technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera’s businesses are its online information business and its therapeutics discovery business. The online information business is a leading provider of information based on the human genome and other biological and medical information. Through the therapeutic discovery business, Celera intends to leverage its genomic and proteomic capabilities to identify drug targets and diagnostic marker candidates, and to discover novel therapeutic candidates. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001. Celera Diagnostics has been established as a joint venture between Applied Biosystems and Celera Genomics. This new venture is focused on discovery, development and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923. Information about Celera is available on the World Wide Web at www.celera.com.


Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.